JPMorgan Chase is facing setbacks regarding its pipeline investments concerning Amphastar Pharmaceuticals.
1 report, 1 independent
Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
JPMorgan Chase is facing setbacks regarding its pipeline investments concerning Amphastar Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
JPMorgan Chase
American multinational banking and financial services holding company
- JPMorgan gave Hilton Worldwide an Overweight rating on July 4, 2025, citing that premium value drives industry-leading net unit growth and EBITDA rises with this growth.
- JPMorgan forecasts Bitcoin delivering a 10% compound annual return, while Justin Sun's Tron blockchain competes directly with Bitcoin.
-
Amphastar Pharmaceuticals
publicly traded American pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyJPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral from Overweight, Brings PT Down to $30 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the 13 Cheap Healthcare Stocks with Huge